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Background: Numerous studies have evidenced that statins can reduce the incidence of cardiovascular disease.
However, the effects of high-dose rosuvastatin (RSV) preloading in patients undergoing percutaneous coronary
intervention (PCI) are controversial.
Objective: We attempted to identify and quantify the potential cardioprotective benefits of high-dose RSV
preloading on final thrombolysis in myocardial infarction (TIMI) flow grade, major adverse cardiac events (MACE),
and peri-procedural myocardial injury (PMI) in patients undergoing PCI.
Methods: Pubmed, EMBASE, Cochrane Central Register of Controlled Trials and ISI Web of Science databases were
systematically searched for randomized controlled trials (RCTs) up to June 2015. We assessed the incidence of
MACE and PMI in all enrolled patients for subgroups stratified by clinical presentation and previous statin therapy
during the follow-up period.
Results: Fourteen trials with 3368 individuals were included in our meta-analysis. High-dose RSV preloading before
PCI lead to a 58 % reduction in MACE (odds ratio [OR] = 0.42, 95 % confidence intervals [CI]: 0.29-0.61, P < 0.00001)
and a 60 % reduction in PMI (OR = 0.40, 95 % CI: 0.25–0.63, P < 0.0001). This procedure also improved the final TIMI
flow grade in patients undergoing PCI (OR = 1.61, 95 % CI: 1.09–2.38, P = 0.02). The benefits on MACE were significant
for both stable angina patients (OR = 0.42, 95 % CI: 0.21-0.87, P = 0.02) and acute coronary syndrome (ACS) patients
(OR = 0.42, 95 % CI: 0.27-0.65, P < 0.0001); and for both statin naïve patients (OR = 0.42, 95 % CI: 0.28-0.64, P < 0.0001) and
previous statin therapy patients (OR = 0.28, 95 % CI: 0.10-0.73, P = 0.01).
Conclusion: High-dose RSV preloading can significantly improve myocardial perfusion and reduce both MACE
and PMI in patients undergoing PCI. The cardioprotective benefits of RSV preloading were significant in not
only stable angina and ACS patients but also statin naïve and previous statin therapy patients. The
cardioprotective benefits of RSV preloading in the follow-up period mainly resulted from a reduction in
spontaneous MI and TVR, especially for ACS and statin naïve patients.
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Percutaneous coronary intervention (PCI) is extensively
used as a reperfusion strategy for coronary artery disease.
Although this procedure is relatively safe and the
procedure-related complications have markedly decreased
with years, peri-procedural myocardial injury (PMI) can still
occur [1]. The most common mechanism is side-branch
occlusion during PCI, and distal embolism, coronary dissec-
tion, and inflammation can also result in PMI. Moreover,
PMI lead to an increased incidence of death at follow-up
(hazard ratio[HR] = 1.2, 95 % CI: 1.04-1.39) after adjust-
ment for baseline covariates [2]. Research previously
focused on the improvement of antithrombotic agents and
vasodilators in decreasing the incidence of cardiac ischemic
events during PCI, while recently it was found that pre-
treatment with statins may significantly reduce major
adverse cardiac events (MACE) and PMI in patients under-
going PCI [3, 4]. It has already been proved in some meta-
analyses of randomized controlled trials (RCTs) [5, 6].
A meta-analysis of 3341 individuals from 13 ran-
domized studies suggested that statin preloading
leads to a significant decrease in 30-day MACE and
PMI in patients undergoing PCI [5]. However, this
research was not able to indicate whether statin pre-
treatment was effective in stable angina or acute cor-
onary syndrome (ACS) patients, as patients were not
assigned to subgroups according to their clinical
presentation. Another updated meta-analysis com-
prising 5526 patients from 24 RCTs indicated that
the cardioprotective benefits of statin preloading on
MACE were effective for statin naïve or ACS
patients [7]. However, recent published trials in which
patients received high-dose rosuvastatin treatment prior
to PCI were not included in this study, and this may have
influenced the final clinical outcomes.
Rosuvastatin (RSV), an inhibitor of 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase, has a number
of pleiotropic effects, including antioxidative, antithrom-
botic, anti-inflammatory, and cardiovascular protective
outcomes. Recently, investigators found a lower rate of
MACE and PMI when patients undergoing PCI
received high-dose RSV pretreatment [8–21]. However,
most of the prospective trials lacked the power to detect
differences from clinical outcomes, due to small size, vary-
ing endpoint definitions, individuals with different clinical
presentation, and diverse regimens of RSV therapy. There-
fore, we systematically evaluated the clinical benefits of
high-dose RSV preloading prior to PCI by conducting a
meta-analysis including all relevant RCTs.
Methods
Search strategy
In this study, we searched PubMed, EMBASE, the
Cochrane Central Register of Controlled Trials and ISIWeb of Science databases up to June 2015 to determine
prospective RCTs comparing the cardiovascular events
of RSV preloading with control (placebo, no-statin, or
current statin therapy) in patients undergoing PCI. Key
words for searching were: “rosuvastatin”, “percutaneous
coronary intervention”, “PCI”, “stents”, “angioplasty”,
“randomized” and “randomly”. We also screened previ-
ous meta-analyses and the references of selected studies.
No language restrictions were used.
Study selection
Trials were included if: (1) they were RCTs involving
humans; (2) they selected patients with ACS (ST-seg-
ment elevation myocardial infarction [STEMI], unstable
angina pectoris, or non-ST-segment elevation myocar-
dial infarction [NSTEMI]) or stable angina; (3) they en-
rolled patients who were statin naïve or undergoing
current therapy with statins; (4) they reported information
on MACE including mortality, spontaneous myocardial
infarction (MI), and target vessel revascularization (TVR)
as well as PMI after PCI. Thrombolysis in myocardial in-
farction (TIMI) classification post-PCI was also recorded.
Exclusion criteria included: (1) non-randomized con-
trolled trials; (2) no outcomes of interest; (3) duplicate re-
ports without additional or updated outcome data.
Data extraction
Two authors (YLP and YT) extracted the data in all the
included trials, and any disagreement was resolved by
discussion with the third author (BL). Firstly, the follow-
ing information was extracted from each study: the first
author’s name, year of publication, sample size of the
trial, type of population, clinical features, regimen of
statins before and after PCI, study duration, and defin-
ition of PMI. Furthermore, we extracted the baseline
characteristics and procedural details in all enrolled
patients. Finally, we extracted data according to the
clinical outcomes including mortality, spontaneous MI,
TVR, and overall MACE during the follow-up period in
each group.
Quality assessment
Study quality was evaluated based on the quality assess-
ment criteria for RCTs in the Cochrane Handbook for
Systematic Reviews of Interventions, including random
sequence generation, allocation concealment, blinding of
investigators, participants and outcome assessors, in-
complete outcome data, selective reporting and other
sources of bias.
End-Points
The primary end-points were MACE and PMI. We used
the PMI definition which was taken from the original ar-
ticles. Secondary end-point was final TIMI flow grade,
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ried out sub-group analyses according to the clinical
condition (ACS and stable angina) or current statin ther-
apy (statin naïve and previous statin therapy).Statistics
Odds ratio (OR) with 95 % confidence intervals (CI) was
used to express dichotomous variables, such as the inci-
dence of PMI, MACE, and post-PCI TIMI flow 3. Het-
erogeneity among studies was quantified using the I2
statistic, defined as I2 > 50 %. In that case, the random
effects model was used; otherwise, the fixed effect model
was chosen. Funnel plots and Egger’s regression test were
used to illustrate the potential publication bias. Results
were considered statistically significant at P < 0.05. Rev-
Man 5.3 software (Cochrane Collaboration, Copenhagen,
Denmark) was used for statistical analysis.Results
Selected studies and baseline characteristics
Based on the search strategy described above, 366 poten-
tially relevant studies were initially included by titles and
abstracts (Fig. 1), and 28 publications were selected.
After reading the full texts of these publications, four-
teen further studies were excluded as they were either
duplicate studies, no outcome of interest reported, or
were non-randomized studies. Finally, 3273 individuals
from fourteen RCTs [8–21] were included, of which
1671 were randomized to the high-dose RSV group and
1602 were randomized to control.366 records retrieved from 
Pubmed (43), EMBASE (179),
Cochrane Central Register of 
Controlled Trials (49), 




150 records were 
excluded due to duplicates
216 potentially relevant studies
188 records excluded based on title 
and abstract:
157 irrelevant to our aim; 
12 reviews;
17 meta-analysis; 
2 not human studies; 
28 full-test of articles reviewed
14 trails were exclude: 
4 duplicate studies; 
7 no outcome of interested reports; 
3 not randomized study;
Fig. 1 Flow diagram of study selection process. RCTs, randomized
controlled trialsTable 1 shows the baseline characteristics of all the
studies, which were published between 2010 and 2014.
There were ten trials [8, 10, 11, 13, 15, 17–21] with only
statin naïve patients, one trial [16] with only previous
statin therapy patients, and three trials [9, 12, 14] with
both of two. Five trials [9, 14–16, 21] included stable an-
gina patients, six trials [8, 11, 13, 17, 19, 20] included
NSTE-ACS patients, two trials [12, 18] included STEMI
patients, and one trial [10] included ACS patients. Thir-
teen trials [8–13, 15–21] included short-term RSV pre-
treatment (immediate to 24 h), while one trial [14]
included relatively long-term RSV pretreatment (5 to
7 days). Other characteristics of the included studies
were follow-up duration and definition of PMI. The
baseline characteristics of the patients and the proced-
ural details in all trials are shown in Table 2. Approxi-
mately two-thirds of the overall population were male,
three-fifths of those had hypertension, and one-third of
those had diabetes. Preprocedural aspirin and clopido-
grel were given to patients in all studies, and patients
among four trials [11, 12, 15, 16] received a loading dose
of clopidogrel (600 mg), while the number of patients
treated with clopidogrel in one trial [10] were unclear.
Patients in a total of 11 trials [8, 11–13, 15–21] received
glycoprotein IIb/IIIa inhibitors (GPIs) at the operators’
discretion, while the remaining trials [9, 10, 14] did not
mention the use of GPIs. Almost four-fifths of the pa-
tients in seven trials [8, 10, 13, 15, 17, 20, 21] underwent
implantation of drug-eluting stents.
Judgments on each risk of bias item for all studies are
shown in Fig. 2. Five of fourteen trials [10, 12, 15, 16, 19]
reported the specific methods used for randomization,
while the remaining included trials [8, 9, 11, 13, 14, 17, 18,
20, 21] did not mention that. Three trials [10, 12, 15] de-
scribed the allocation concealments in detail, two trials
[11, 14] did not use allocation concealments, and alloca-
tion concealments were not described in the remaining
trials.[8, 9, 13, 16–21] Blinded methods were used in four
trials, three of which [10, 12, 13] used a blinded approach
for investigators, participants and outcome assessors,
while one trial [17] was only blinded for outcome asses-
sors. None of the included studies had incomplete out-
come data, selective reporting and other sources of bias.
Effect of high-dose RSV preloading before PCI on
coronary perfusion
Effect of high-dose RSV preloading before PCI on
post-PCI TIMI flow grade 3 were analyzed in ten
trials [9, 10, 13–15, 17–21]. Fixed effect model was
chosen based on no potential heterogeneity across tri-
als (I2 = 0 %, P = 0.91). The overall outcome indicated
that RSV preloading lead to a 61 % relative increase
in post-PCI TIMI flow grade 3 (OR = 1.61, 95 % CI:
1.09-2.38, P = 0.02; Fig. 3).







Timing before PCI Regimen after PCI Follow-up Definition of PMI
Gao [19] 59/58 Statin naïve NSTE-ACS RSV 20 mg 12 h and 10 mg
2 h before PCI VS placebo
treatment
RSV 10 mg/d for
at least 1 year
6 months CKMB > 3 UNL
Li [18] 103/ 100 Statin naïve STEMI RSV 20 mg before PCI
VS RSV 10 mg treatment
RSV 10 mg/d for
3 months
30 days CKMB > 3 UNL
Luo [17] 31/36 Statin naïve NSTE-ACS RSV 20 mg 12 h and 20 mg
2 h before PCI VS no statin
pretreatment
RSV 10 mg/d 30 days cTnI > 3 UNL
Takano [14] 104/ 106 Mixed Stable
Angina
RSV 20 mg 5-7day before
PCI VS RSV 2.5 mg treatment
RSV 10 mg/d VS
RSV 2.5 mg/d
12 months CKMB > 3 UNL
Wang [13] 62/63 Statin naïve NSTE-ACS RSV 20 mg before PCI
VS placebo pretreatment
RSV 10 mg/d for
at least 30 days
30 days CKMB > 3 UNL
Xie [8] 79/80 Statin naïve NSTE-ACS RSV 20 mg 12 h and 20 mg
2 h before PCI VS placebo
treatment
RSV 10 mg/d 30 days cTnI > 5 UNL
Yun [20] 225/ 220 Statin naïve NSTE-ACS RSV 40 mg before PCI
VS no statin pretreament
RSV 10 mg/d 12 months CKMB > 2 UNL
Veselka [9] 220/ 225 Mixed Stable
Angina
RSV 20 mg 12 h and 20 mg
before PCI VS no statin
pretreatment
Statin treatment In hospital cTnI > 5 UNL
Cay [21] 153/ 146 Statin naïve Stable
Angina
RSV 40 mg 24 h before
PCI VS no RSV pretreatment
RSV 10-40 mg/d In hospital CKMB > 3 UNL
Leoncini [11] 252/ 252 Statin naïve NSTE-ACS RSV 40 mg 24 h and 20 mg
before PCI VS no statin
pretreatment
RSV 20 mg/d VS
atorvastatin 40 mg/d
6 months CKMB > 3 UNL
ROMA [16] 80/80 Statin naïve Stable
Angina
RSV 40 mg 24 h before PCI
VS no RSV pretreatment
RSV 20 mg/d 12 months CKMB > 3 UUNL




RSV 40 mg 24 h before PCI
VS no statin pretreatment
RSV 20 mg/d 12 months CKMB > 3 UNL
Ko [12] 62/70 Mixed STEMI RSV 40 mg before PCI VS
placebo treatment
RSV 40 mg VS 10 mg both for
7 days, and a further 10 mg/d
in both groups for 3 weeks
3 months NA
Liang [10] 66/66 Statin naïve ACS RSV 40 mg 4 h VS RSV 10
mg before PCI
RSV 10 mg/d for at least
1 year
6 months NA
RSV rosuvastatin, CK-MB creatine kinase-myocardial band, cTnI cardiac troponin I, UNL upper normal limit, Mixed Statin naïve and prior statin treatment, PMI
periprocedural myocardial infarction, ACS acute coronary syndrome, NSTE-ACS non-ST segment elevation ACS, STEMI ST segment elevation myocardial infarction,
NA not available
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outcomes
Effect of high-dose RSV preloading before PCI on
MACE were analyzed in 12 trials [8, 10–20]. Fixed effect
model was chosen based on no potential heterogeneity
across trials (I2 = 0 %, P = 0.89). The overall outcome for
MACE showed that RSV preloading lead to a 58 % rela-
tive reduction in MACE (OR = 0.42, 95 % CI: 0.29-0.61,
P < 0.00001; Fig. 4). Effect of RSV preloading before PCI
on PMI were analyzed in 12 trials [8, 9, 11, 13–21].
Random effects model was used due to substantial het-
erogeneity between the two groups (I2 = 53 %, P = 0.01).
The overall outcome for PMI showed that RSV
preloading lead to a 60 % relative reduction in PMI
(OR = 0.40, 95 % CI: 0.25-0.63, P < 0.0001; Fig. 5).Subgroup analyses with different types of coronary
syndrome
In order to assess the effect of high-dose RSV preloading
in patients with different disease status before undergo-
ing PCI, we divided all enrolled patients into two groups:
stable angina and ACS. Due to the fixed effect model,
RSV preloading before PCI lead to a 58 % relative reduc-
tion in MACE for stable angina patients (OR = 0.42,
95 % CI: 0.21-0.87, P = 0.02; I2 = 10 %); and a 58 % rela-
tive reduction in MACE for ACS patients (OR = 0.42,
95 % CI: 0.27-0.65, P < 0.0001; I2 = 0 %) (Fig. 4). We also
evaluated the stable angina and ACS subgroup for their
effects on PMI. Due to the random effects model, RSV
preloading before PCI lead to a 63 % reduction in PMI
for stable angina patients (OR = 0.37, 95 % CI: 0.14-0.97,
Table 2 Baseline clinical characteristics and procedural details in the overall population
Variables High-dose of RSV n/population (%) Control n/population (%)
Number of patients 1671/3273 (51.1 %) 1602/3273 (48.9 %)
Male 1150/1671 (68.8 %) 1075/1602 (67.1 %)
Hypertension 1088/1671 (65.1 %) 988/1602 (61.7 %)
Diabetes Mellitus 473/1671 (28.3 %) 449/1602 (28.0 %)
Smoker 592/1606 (36.9 %) 573/1542 (37.2 %)
Previous MI 223/1067 (20.9 %) 224/1069 (21.0 %)
Previous PCI 160/1019 (15.7 %) 143/1017 (14.1 %)
Stable angina 732/1671 (43.8 %) 657/1602 (41.0 %)
NSTEMI 759/1671 (45.4 %) 759/1602 (47.3 %)
STEMI 181/1671 (10.8 %) 188/1602 (11.7 %)
Multi-vessel disease 198/644 (30.7 %) 157/633 (24.8 %)
B2/C lesions 654/918 (71.2 %) 590/855 (69.0 %)
Thrombus 122/757 (16.1 %) 135/763 (17.7 %)
LM 16/700 (2.3 %) 25/709 (3.5 %)
LAD 666/1253 (53.2 %) 619/1174 (52.7 %)
LCX 360/1315 (27.3 %) 354/1244 (28.4 %)
RCA 393/1253 (31.4 %) 368/1174 (31.3 %)
Multiple vessel PCI 216/644 (33.5 %) 203/768 (26.4 %)
Aspirin 1624/1671 (97.2 %) 1548/1602 (96.6 %)
Clopidogrel 1599/1605 (99.6 %) 1530/1536 (99.6 %)
β-blockers 952/1393 (68.3 %) 979/1402 (69.8 %)
ACEI/ARB 910/1393 (65.3 %) 953/1402 (67.9 %)
Glycoprotein IIb/IIIa inhibitors 76/1025 (7.4 %) 103/959 (10.7 %)
Numbers of DES 560/696 (80.5 %) 556/691 (80.5 %)
Previous MI previous myocardial infarction, Previous PCI previous percutaneous coronary intervention, NSTE-ACS non-ST segment elevation acute coronary
syndrome, STEMI ST segment elevation myocardial infarction, LM, left main, LAD left anterior descending, LCX left circumflex, RCA right coronary artery, DES
drug-eluting stent
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ACS patients (OR = 0.43, 95 % CI: 0.29-0.65, P < 0.0001;
I2 = 0 %) (Fig. 5).
Subgroup analyses based on previous statin therapy
In order to confirm whether current statin therapy be-
fore high-dose RSV preloading prior to PCI affected the
incidence of MACE and PMI, we evaluated subgroups of
patients based on their statin therapy before PCI in 11
trials [8, 10, 11, 13–20]. Due to the fixed effect model,
RSV preloading lead to a 60 % relative reduction of
MACE in all the enrolled patients (OR = 0.40, 95 % CI:
0.27-0.58, P < 0.00001; I2 = 0 %), a 58 % relative reduc-
tion in the statin naïve group (OR = 0.42, 95 % CI: 0.28-
0.64, P < 0.0001; I2 = 0 %) and a 72 % relative reduction
in the previous statin therapy group (OR = 0.28, 95 % CI:
0.10-0.73, P = 0.01; I2 = 0 %) (Fig. 6). Due to the fixed ef-
fect model, RSV preloading lead to a 67 % relative re-
duction of PMI in all the enrolled patients (OR = 0.33,
95 % CI: 0.25-0.45, P < 0.00001; I2 = 0 %), a 66 % relativereduction in the statin naïve group (OR = 0.34, 95 % CI:
0.24-0.49, P < 0.00001; I2 = 0 %), and a 69 % relative re-
duction in the previous statin therapy group (OR = 0.31,
95 % CI: 0.17-0.55, P < 0.0001; I2 = 39 %) (Fig. 7).
Effects of high-dose RSV preloading on follow-up
outcome
Table 3 depicts overall MACE including mortality, spon-
taneous MI, and TVR during follow-up. As mentioned
above, the overall MACE was significantly reduced in all
the enrolled patients. When stratified by type of disease,
high-dose RSV preloading before PCI failed to decrease
overall mortality (P = 0.42), spontaneous MI (P = 0.34)
and TVR (P = 0.05) in patients with stable angina, and
also didn’t reduce overall mortality in ACS patients
(P = 0.09). However, RSV preloading before PCI signifi-
cantly reduced the incidence of spontaneous MI (P = 0.02)
and TVR (P = 0.01) in ACS patients. According to previ-
ous statin therapy, high-dose RSV preloading had no
influence on overall mortality (P = 0.3), spontaneous MI
Fig. 2 Quality assessment of included studies in this review a. Risk of bias graph; b. Risk of bias summary
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patients. Moreover, the overall mortality (P = 0.09) was
not significantly reduced in statin naïve patients, while
the incidence of spontaneous MI (P = 0.02) and TVR
(P = 0.008) was significantly decreased.
Publication bias
As shown in Fig. 8, the results didn’t provide any evi-
dence of potential publication bias based on funnel plots
and Egger’s regression test. Funnel plots for MACE were
generated using a fixed effect model (P = 0.139 > 0.05)
and for PMI were generated using a random effects
model (P = 0.273 > 0.05).Fig. 3 ORs for final TIMI flow grade in overall population. Abbreviations: CIDiscussion
Our analysis of 3273 individuals from 14 RCTs demon-
stated that high-dose RSV preloading before PCI can
significantly improve the post-PCI TIMI flow grade and
reduce the incidence of MACE and PMI. In addition,
according to different disease presentations, high-dose
RSV preloading can significantly decrease the incidence
of MACE and PMI in both stable angina and ACS
patients; when stratified according to current statin ther-
apy, high-dose RSV preloading can also significantly
reduce the incidence of MACE and PMI in both statin
naïve and previous statin therapy patients. Moreover, ac-
cording to the follow-up data, high-dose RSV preloading, confidence interval; M-H, Mantel-Haenszel
Fig. 4 ORs for MACE in patients with different coronary syndromes. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel
Fig. 5 ORs for PMI in patients with different coronary syndromes. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel
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Fig. 6 ORs for MACE in patients with different statin therapy. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel
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MI and TVR in ACS and statin naïve patients, but failed
to improve clinical outcomes in both patients with stable
angina and current statin therapy.
We confirm and extend the meta-analyses by Benjo
A.M [22] and Wang L [7] which indicated a reduction in
PMI and MACE with statin preloading before PCI.
Benjo et al. selected 1591 patients from 14 RCTs andFig. 7 ORs for PMI in patients with different statin therapy. Abbreviations: Cfound a 56 % relative reduction in PMI and a 41 % re-
duction in clinical events in patients with current statin
treatment before PCI. Wang L et al. selected 24 RCTs
with 5526 patients and demonstrated that statin preload-
ing lead to a 59 % relative reduction in PMI and a 39 %
relative reduction in MACE. These two studies were
credible and conclusive, while different types of statins
may have various effects on clinical events in bothI, confidence interval; M-H, Mantel-Haenszel
Table 3 Clinical events during follow-up
Events High-dose of RSV n (%) Control n (%) P
Stable
Death 2(0.6 %) 3(1.0 %) 0.42
Spontaneous MI 5(1.4 %) 7(2.4 %) 0.34
TVR 5(1.4 %) 12(4.2 %) 0.05
MACE 12(3.3 %) 22(7.7 %) 0.02
ACS
Death 7(0.7 %) 15(1.6 %) 0.09
Spontaneous MI 7(0.7 %) 20(2.1 %) 0.02
TVR 19(2.0 %) 37(3.9 %) 0.01
MACE 33(3.5 %) 72(7.6 %) <0.0001
Overall
Death 9(0.7 %) 18(1.5 %) 0.06
Spontaneous MI 12(0.9 %) 27(2.2 %) 0.01
TVR 24(1.8 %) 49(4.0 %) 0.002
MACE 45(3.5 %) 94(7.6 %) <0.00001
Statin naïve
Death 7(0.7 %) 15(1.6 %) 0.09
Spontaneous MI 8(0.8 %) 21(2.2 %) 0.02
TVR 20(2.1 %) 40(4.2 %) 0.008
MACE 35(3.7 %) 76(8.0 %) <0.0001
Prior statin treatment
Death 1(0.4 %) 2(1.2 %) 0.3
Spontaneous MI 2(0.8 %) 5(3.0 %) 0.13
TVR 3(1.2 %) 7(4.2 %) 0.09
MACE 6(2.4 %) 14(8.4 %) 0.01
Overall
Death 8(0.7 %) 17(1.5 %) 0.05
Spontaneous MI 10(0.8 %) 26(2.3 %) 0.005
TVR 23(1.9 %) 47(4.2 %) 0.002
MACE 41(3.4 %) 90(8.0 %) <0.00001
ACS acute coronary syndrome, Spontaneous MI spontaneous myocardial
infarction, TVR target vessel revascularization, MACE major adverse
cardiovascular events
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proved their hypothesis, patients with STEMI and
current statin treatment were excluded, which led to the
lack of identifying the effects of statin preloading in the
overall population. Data on patients with chronic statin
therapy were included in the latter study, however, re-
cent trials on high-dose RSV pretreatment, which were
published after this meta-analysis, drew controversial
conclusions concerning the cardioprotective benefits of
this treatment on PMI and MACE. Our meta-analysis
demonstrated that RSV preloading before PCI lead to a
60 % relative reduction in PMI (P < 0.0001) and a 58 % rela-
tive reduction in MACE (P < 0.00001). The cardioprotectiveeffects of RSV were consistent in not only stable angina
and ACS patients but also statin naïve and previous statin
therapy patients. High-dose RSV preloading can signifi-
cantly reduce the clinical outcome in the overall popula-
tion, which was mainly due to a reduction of TVR,
especially for ACS and statin naïve patients. Although these
benefits of RSV preloading failed to decrease overall mor-
tality in the enrolled patients, they reduced the incidence of
spontaneous MI and TVR in ACS and statin naïve patients.
PMI is characterized by any cardiac serum marker
(creatine kinase-myocardial band [CK-MB]; cardiac
troponin I [cTnI]) elevation three times or more the
upper limit of normal (ULN) after PCI, which has been
shown to occur in approximately 15-20 % of patients
undergoing PCI procedures in spite of different definitions
used [23]. The pathogenic mechanisms of PMI include
side-branch occlusion, distal embolism, endothelial dys-
function, oxidative stress, and inflammation [1]. In order
to reduce the incidence of PMI, researchers have focused
on antiplatelet agents, anticoagulants, vasodilators, and
beta-blockers to improve coronary blood flow after PCI.
More recently, some studies [21, 24, 25] have suggested
that the reduction of the MACE and PMI in patients
undergoing PCI was associated with HMG-CoA reductase
inhibitors (statins), in particular atorvastatin and RSV. In
addition to its lipid-lowering effects, RSV exerts many
cardioprotective effects including an improvement in
endothelial function, antithrombotic actions, inhibition
of thrombosis, plaque stabilization, and suppression of
inflammation. These may partly account for the cardio-
protective effects of RSV on spontaneous MI and TVR
in ACS patients due to the high inflammatory status in
these patients, which is associated with a high predict-
ive value for the occurrence of MACE [26].
The possible mechanisms underlying the early protect-
ive action of RSV are unclear, as the enrolled patients
were given a short-term high-dose of RSV before PCI,
which may not have had a significant influence on choles-
terol level. Vilahur G et al. [27] showed that RSV enhanced
PKC, Erk2, AKT/PKB signal pathways and its downstream
effectors to attenuate inflammation and cardiomyocyte
apoptosis in the peri-infarcted zone and reduce infarct size
in pigs. RSV has been shown to enhance the protective
effects of ischemic post-conditioning against myocar-
dial ischemia and reperfusion (I/R) injury in rats via
activating PI3K/Akt/eNOS signaling pathway [28]. Ni-
trous oxide (NO), due to the activation of endothelial
nitric oxide synthase (eNOS), can decrease leukocyte
activation and infiltration, platelet activation and ag-
gregation, vasoconstriction and contractile dysfunction
[1]. These beneficial cardiac effects of statins are ab-
sent in eNOS knockout mice and can be reversed by
using the specific inhibitor of PI3K kinase and eNOS
[29, 30]. In our meta-analysis, cardiac benefits of high-
a b
Fig. 8 Funnel plots of the included studies. a. Funnel plots for MACE; b. Funnel plots for PMI. The results show no potential publication bias for
MACE and PMI. Abbreviations: OR, odds ratio; SE, standard error
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dence of spontaneous MI and TVR in statin naïve pa-
tients, but had no effects on previous statin therapy
patients. Patients with previous statin therapy are
probably in a condition of dyslipidaemia. They are
likely to take some nutraceuticals (resveratrol, grape
seed, curcumin, zinc, and fish oil) and antioxidants
(carotenoids, vitamins A, C, and E) in their daily diet
to decrease the plasma lipids, which can influence the
overall outcomes [31, 32]. Hence, we speculate that the
cardiovascular benefits of short-term high-dose RSV
preloading might be counteracted by long-term intake
of statin, nutraceuticals, or antioxidants. Interestingly,
chronic statin therapy failed to exert a cardioprotective
effect that wanes with time associated with increased
levels of PTEN (phosphatase and tensin homolog de-
leted on chromosome ten, an inhibitor of PI3K) in SD
rats and these can partly attenuate the cardioprotective
effects of high-dose RSV preloading, which may par-
tially confirm our speculation [33].
The results of our study are different from those by
Veselka et al. [9], who demonstrated that high-dose RSV
therapy had no effects on the incidence of PMI in pa-
tients with stable angina. We compared the results when
included and excluded Veselka’s trial data. The signifi-
cant effects on PMI were unchanged, while excluding
Veselka’s data changed the homogeneity in the stable an-
gina group (I2 = 81 to 16 %) and the overall population
(I2 = 53 to 0 %). We indicated that the main heterogeneity
was due to the different doses and types of statins admin-
istered. 36 of 220 patients (16.4 %) in the high-dose RSV
group and 51 of 225 patients (22.6 %) in control received
long-term high-dose statin therapy (atorvastatin 40 or
80 mg, RSV 20 or 40 mg). This may partially explain why
high-dose RSV treatment before PCI failed to reduce theincidence of PMI in their study, as the beneficial cardio-
protection effect of transient high-dose RSV may be elimi-
nated by chronic high-dose statin therapy.
Statin therapy is only recommended as secondary pre-
vention of cardiovascular outcomes in the present guide-
lines for ACS and PCI [34, 35]. However, high-dose RSV
preloading before PCI can reduce the incidence of
MACE and PMI, which is not recommended in these
guidelines. Our analysis adds strength and power to
current recommendations and potentially expands the
use of RSV before PCI.
Study limitations
There were several limitations in our meta-analysis.
Firstly, the trials included did not use a uniform RSV
regimen, definition of PMI, or clinical outcomes exam-
ined. Different doses and duration of RSV treatment in
patients with different backgrounds may have various
effects on MACE and PMI. Secondly, seven of fourteen
trials included not long enough follow-up period which
was no more than 30 days of observation. Hence, more
high quality RCTs are required to identify the beneficial
cardiac effects of RSV preloading before PCI over a longer
follow-up period. Thirdly, due to a lack of patient-level
data, we failed to analyze the effect of high-dose RSV pre-
loading on peri-procedural high-sensitivity C-reactive pro-
tein (hs-CRP) level variation (post-intervention hs-CRP
minus baseline hs-CRP). In the same way, we are not able
to provide subgroup analyses based on gender due to a
lack of patient-level data. Hence, further studies are
required to investigate whether high-dose RSV preloading
plays a different role in men and women. Finally, there
was potential heterogeneity in our study due to limited
study numbers, small sample sizes, different protocols,
and patients with various backgrounds.
Pan et al. Lipids in Health and Disease  (2015) 14:97 Page 11 of 12Conclusion
High-dose RSV preloading can significantly improve
myocardial perfusion and reduce MACE and PMI in
patients undergoing PCI. The cardioprotective effects of
RSV preloading were significant in not only stable an-
gina and ACS patients but also statin naïve and previous
statin therapy patients. The cardioprotective effects of
high-dose RSV were mainly due to the reduction in
spontaneous MI and TVR, especially in ACS and statin
naïve patients. Therefore, it indicates that RSV preloading
before PCI should be used in consideration of the disease
presentation and current statin therapy in patients before
undergoing PCI.
Abbreviations
RSV: Rosuvastatin; PCI: Percutaneous coronary intervention; PMI: Peri-procedural
myocardial injury; MACE: Major adverse cardiac events; RCTs: Randomized
controlled trials; MI: Myocardial infarction; TVR: Target vessel revascularization;
HR: Hazard ratio; OR: Odds ratio; CI: Confidence intervals; ACS: Acute coronary
syndrome; HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A;
TIMI: Thrombolysis in myocardial infarction; hs-CRP: High-sensitivity C-reactive
protein; GPIs: Glycoprotein IIb/IIIa inhibitors; ULN: Upper limit of normal; I/R
injury: Ischemia and reperfusion injury; NO: Nitrous oxide; eNOS: Nitric oxide
synthase; PTEN: Phosphatase and tensin homolog deleted on chromosome ten;
CK-MB: Creatine kinase-myocardial band; cTnI: cardiac troponin I; NSTE-ACS:
Non-ST segment elevation ACS; STEMI: ST segment elevation myocardial
infarction; NA: Not available; LM: Left main; LAD: Left anterior descending;
LCX: Left circumflex; RCA: Right coronary artery; DES: Drug-eluting stent;
M-H: Mantel-Haenszel; SE: Standard error.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XDL contributed to the overall design of the study. YLP and YT performed
the data analysis, interpreted the results. YLP wrote section of the initial draft.
BL helped with the data analysis. All authors read and approved the final
version of the manuscript.
Acknowledgments
This study was funded by the Funding Program of Liaoning Educational
Committee (Grant No. L2013314).
Author details
1Department of Cardiology, Shengjing Hospital of China Medical University,
Shenyang, China. 2Department of Anesthsia, Shengjing Hospital of China
Medical University, Shenyang, China.
Received: 5 August 2015 Accepted: 16 August 2015
References
1. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J.
2005;26:2493–519.
2. Erbel R, Wijns W. The Year in Cardiology 2013: coronary intervention.
Eur Heart J. 2014;35:313–20.
3. Tentzeris I, Rohla M, Jarai R, Farhan S, Freynhofer MK, Unger G, et al.
Influence of High-Dose Highly Efficient Statins on Short-Term Mortality in
Patients Undergoing Percutaneous Coronary Intervention With Stenting for
Acute Coronary Syndromes. Am J Cardiol. 2014;113:1099–104.
4. Kim JW, Yun KH, Kim EK, Kim YC, Joe D-Y, Ko JS, et al. Effect of High Dose
Rosuvastatin Loading before Primary Percutaneous Coronary Intervention
on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction.
Korean Circulation J. 2014;44:76–81.
5. Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, et al. Clinical
benefit of statin pretreatment in patients undergoing percutaneouscoronary intervention: A collaborative patient-level meta-analysis of 13
randomized studies. Circulation. 2011;123:1622–32.
6. Winchester DE, Wen X, Xie L, Bavry AA. Evidence of pre-procedural statin
therapy: A meta-analysis of randomized trials. J Am Coll Cardiol.
2010;56:1099–109.
7. Wang L, Peng P, Zhang O, Xu X, Yang S, Zhao Y, et al. High-dose statin
pretreatment decreases periprocedural myocardial infarction and
cardiovascular events in patients undergoing elective percutaneous
coronary intervention: A meta-analysis of twenty-four randomized
controlled trials. PLoS ONE. 2014;9, e113352.
8. Xie W, Li P, Wang Z, Chen J, Lin Z, Liang X, et al. Rosuvastatin may
reduce the incidence of cardiovascular events in patients with acute
coronary syndromes receiving percutaneous coronary intervention by
suppressing miR-155/SHIP-1 signaling pathway. Cardiovasc Ther.
2014;32:276–82.
9. Veselka J, Hajek P, Tomasov P, Tesar D, Bruhova H, Matejovic M, et al. Effect
of rosuvastatin therapy on troponin I release following percutaneous
coronary intervention in nonemergency patients (from the TIP 3 study).
Am J Cardiol. 2014;113:446–51.
10. Liang D, Zhang Q, Yang H, Zhang R, Yan W, Gao H, et al. Anti-oxidative
stress effect of loading-dose rosuvastatin prior to percutaneous coronary
intervention in patients with acute coronary syndrome: a prospective
randomized controlled clinical trial. Clin Drug Investig. 2014;34:773–81.
11. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early
high-dose rosuvastatin for contrast-induced nephropathy prevention in
acute coronary syndrome: Results from the PRATO-ACS Study (Protective
Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute
kidney injury and myocardial damage in patients with Acute Coronary
Syndrome). J Am Coll Cardiol. 2014;63:71–9.
12. Ko Y-G, Won H, Shin D-H, Kim J-S, Kim B-K, Choi D, et al. Efficacy of Early
Intensive Rosuvastatin Therapy in Patients With ST-Segment Elevation
Myocardial Infarction Undergoing Primary Percutaneous Coronary
Intervention (ROSEMARY Study). Am J Cardiol. 2014;114:29–35.
13. Wang Z, Dai H, Xing M, Yu Z, Lin X, Wang S, et al. Effect of a single high
loading dose of rosuvastatin on percutaneous coronary intervention for
acute coronary syndromes. J Cardiovasc Pharmacol Ther. 2013;18:327–33.
14. Takano H, Ohba T, Yamamoto E, Miyachi H, Inui K, Kawanaka H, et al.
Usefulness of rosuvastatin to prevent periprocedural myocardial injury in
patients undergoing elective coronary intervention. Am J Cardiol.
2013;111:1688–93.
15. Sardella G, Lucisano L, Mancone M, Conti G, Calcagno S, Stio RE, et al.
Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment
in patients undergoing elective PCI to reduce the incidence of MyocArdial
periprocedural necrosis. The ROMA II trial. Int J Cardiol. 2013;168:3715–20.
16. Sardella G, Conti G, Donahue M, Mancone M, Canali E, Carlo C, et al.
Rosuvastatin pretreatment in patients undergoing elective PCI to reduce
the incidence of myocardial periprocedural necrosis: The ROMA trial.
Catheter Cardiovasc Interv. 2013;81:E36–43.
17. Luo J, Li J, Shen X, Hu X, Fang Z, Lv X, et al. The effects and mechanisms of
high loading dose rosuvastatin therapy before percutaneous coronary
intervention in patients with acute coronary syndrome. Int J Cardiol.
2013;168:2350–3.
18. Li P, Huang C, Gan J, Liang X, Chen J, Wang Z. Efficacy of high-dose
rosuvastatin loading before primary percutaneous coronary intervention in
ST-segment elevation myocardial infarction. Chin J Clin Pharmacol.
2013;29:732–5.
19. Gao Y, Jia Z-m, Sun Y-j, Zhang Z-h, Ren L-n, Qi G-x. Effect of high-dose
rosuvastatin loading before percutaneous coronary intervention in female
patients with non-ST-segment elevation acute coronary syndrome. Chin
Med J. 2012;125:2250–4.
20. Yun KH, Oh SK, Rhee SJ, Yoo NJ, Kim NH, Jeong JW. 12-month follow-up
results of high dose rosuvastatin loading before percutaneous coronary
intervention in patients with acute coronary syndrome. Int J Cardiol.
2011;146:68–72.
21. Cay S, Cagirci G, Sen N, Balbay Y, Durmaz T, Aydogdu S. Prevention of
peri-procedural myocardial injury using a single high loading dose of
rosuvastatin. Cardiovasc Drugs Ther. 2010;24:41–7.
22. Benjo AM, El-Hayek GE, Messerli F, DiNicolantonio JJ, Hong MK, Aziz EF,
et al. High dose statin loading prior to percutaneous coronary intervention
decreases cardiovascular events: A meta-analysis of randomized controlled
trials. Catheter Cardiovasc Interv. 2015;85:53–60.
Pan et al. Lipids in Health and Disease  (2015) 14:97 Page 12 of 1223. Norris DM, Anderson JR. Statin loading before percutaneous coronary
intervention to reduce periprocedural myocardial infarction. Cardiol Rev.
2012;20:319–24.
24. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A.
Efficacy of atorvastatin reload in patients on chronic statin therapy
undergoing percutaneous coronary intervention: results of the
ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage
During Angioplasty) Randomized Trial. J Am Coll Cardiol. 2009;54:558–65.
25. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al.
Atorvastatin pretreatment improves outcomes in patients with acute
coronary syndromes undergoing early percutaneous coronary intervention:
results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol.
2007;49:1272–8.
26. Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, et al. Response of
high-sensitivity C-reactive protein to percutaneous coronary intervention in
patients with acute coronary syndrome. Heart Vessels. 2009;24:175–80.
27. Vilahur G, Casani L, Pena E, Duran X, Juan-Babot O, Badimon L. Induction of
RISK by HMG-CoA reductase inhibition affords cardioprotection after
myocardial infarction. Atherosclerosis. 2009;206:95–101.
28. Cai W, Fang J, Chen Z, Lin Y, Wu L, Chen L. Rosuvastatin enhances the
protective effects of ischemic postconditioning on myocardial
ischaemia-reperfusion injury in type 2 diabetic rat. Chin J Cardiol.
2010;38:814–8.
29. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion,
and independent of lipid lowering, protects the myocardium by
up-regulating a pro-survival pathway. J Am Coll Cardiol. 2003;41:508–15.
30. Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S, et al. Atorvastatin-induced
cardioprotection is mediated by increasing inducible nitric oxide synthase and
consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ
Physiol. 2006;290:H1960–8.
31. Ciccone MM, Cortese F, Gesualdo M, Carbonara S, Zito A, Ricci G, et al.
Dietary Intake of Carotenoids and Their Antioxidant and Anti-Inflammatory
Effects in Cardiovascular Care. Mediators Inflamm. 2013;2013:782137.
32. Scicchitano P, Cameli M, Maiello M, Modesti PA, Muiesan ML, Novo S, et al.
Nutraceuticals and dyslipidaemia: Beyond the common therapeutics.
J Funct Foods. 2014;6:11–32.
33. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium
against ischemia/reperfusion injury after chronic atorvastatin treatment is
recaptured by acute atorvastatin treatment: a potential role for phosphatase
and tensin homolog deleted on chromosome ten? J Am Coll Cardiol.
2005;45:1287–91.
34. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr
DR, et al. AHA/ACC guideline for the management of patients with
non-ST-elevation acute coronary syndromes: a report of the American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines. Circulation. 2014;2014(130):e344–426.
35. Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, et al. ESC/EACTS
Guidelines on myocardial revascularization: the Task Force on Myocardial
Revascularization of the European Society of Cardiology (ESC) and the
European Association for Cardio-Thoracic Surgery (EACTS). Developed with
the special contribution of the European Association of Percutaneous
Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg.
2014;2014(46):517–92.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
